Shanghai Fosun Pharmaceutical (SHA:600196) obtained registrations for two drugs from China's food and drug administrator, according to a Monday filing with the Shanghai bourse.
Polymyxin B sulfate for injection is intended for treating gram-negative bacterial infections resistant to conventional therapy, while labetalol hydrochloride injection is used to treat severe hypertension and for controlling hypotension during anesthesia.
Shares of the pharmaceutical company were down 1% in recent trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。